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Abstract
Background and Purpose: Carbonic anhydrase IX (CAIX) plays a pivotal role in pH homeostasis, which is essential for tumor
cell survival. We examined the effect of the CAIX inhibitor 4-(39(30,50-dimethylphenyl)-ureido)phenyl sulfamate (S4) on the
tumor microenvironment in a laryngeal tumor model by analyzing proliferation, apoptosis, necrosis, hypoxia, metabolism
and CAIX ectodomain shedding.
Methods: SCCNij202 tumor bearing-mice were treated with S4 for 1, 3 or 5 days. CAIX ectodomain shedding was measured
in the serum after therapy. Effects on tumor cell proliferation, apoptosis, necrosis, hypoxia (pimonidazole) and CAIX were
investigated with quantitative immunohistochemistry. Metabolic transporters and enzymes were quantified with qPCR.
Results: CAIX ectodomain shedding decreased after treatment with S4 (p,0.01). S4 therapy did neither influence tumor cell
proliferation nor the amount of apoptosis and necrosis. Hypoxia (pimonidazole) and CAIX expression were also not affected
by S4. CHOP and MMP9 mRNA as a reference of intracellular pH did not change upon treatment with S4. Compensatory
mechanisms of pH homeostasis at the mRNA level were not observed.
Conclusion: As the clinical and biological meaning of the decrease in CAIX ectodomain shedding after S4 therapy is not
clear, studies are required to elucidate whether the CAIX ectodomain has a paracrine or autocrine signaling function in
cancer biology. S4 did not influence the amount of proliferation, apoptosis, necrosis and hypoxia. Therefore, it is unlikely
that S4 can be used as single agent to influence tumor cell kill and proliferation, and to target primary tumor growth.
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Introduction
Tumor metabolism produces large amounts of acids by
converting glucose into lactate acid and protons through glycolysis,
and carbon dioxide (CO2) through oxidative phosphorylation and
the pentose phosphate pathway [1]. Since many intracellular
processes, such as ATP production, protein synthesis and cell
proliferation, require a close regulation of the intracellular pH,
tumor cells must develop strategies to protect the cytosol from
cytotoxic acidosis and to survive [2]. An important regulator of pH
homeostasis is the hypoxia-inducible factor 1 (HIF-1), which
enhances the expression of several membrane-located transporters
and enzymes including monocarboxylate transporters (MCT), and
carbonic anhydrase IX and XII (CAIX, CAXII) [1–3]. Also
sodium-hydrogen exchangers (NHE) and plasma membrane
proton pump vacuolar ATPase (V-ATPase) are involved in pH
regulation [3]. Overexpression of the V-ATPase ATP6V1C1
mediates intracellular pH regulation in head and neck squamous
cell carcinomas [4]. Tumor pH homeostasis maintains a slightly
alkaline intracellular pH (7.2–7.4), whereas the extracellular pH is
more acidic (6.5–7.0) [3,5].
CAIX and CAXII are transmembrane zinc-containing metal-
loenzymes that catalyze the reversible hydration of carbon dioxide
into bicarbonate and protons. Since the active site of CAIX and
CAXII resides in the extracellular space, this enzymatic reaction
contributes to extracellular acidification, which promotes tumor
cell migration, invasion and metastasis formation [2,3,6]. Further-
more, CAIX and CAXII are involved in maintaining an alkaline
intracellular pH, as the bicarbonate ion resulting from the catalytic
reaction can be imported into the cell through chloride/
bicarbonate exchangers and sodium/bicarbonate co-transporters.
This intracellular alkalinization supports cell growth and survival
[2,3,5–7]. CAIX has higher extracellular activity than CAXII [7–
9]. In normal tissues, CAIX is only expressed in the mucosa of the
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glandular stomach, large bile ducts and peritoneal lining, while
CAXII is also expressed in the urinary tract, and skin and soft
tissues. CAIX overexpression is found in several types of solid
tumors including head and neck cancer, lung carcinomas,
esophageal cancer and soft tissue sarcomas. In most studies,
CAIX expression is associated with a poor prognosis [2,3,10],
while the prognostic significance of CAXII is controversial
[2,11,12].
On the basis of the prognostic significance of CAIX and its
important role in pH regulation, this enzyme could be a pivotal
target for cancer therapy. Therefore, several CA inhibitors have
been developed including the sulfonamides and their isoesters
(sulfamates, sulfamides) [13]. These targeting agents inhibit CAIX
and CAXII by binding to the catalytic zinc ion in the active site of
the enzyme and thereby blocking its function [3]. Of this group of
inhibitors, 4-(39(30,50-dimethylphenyl)-ureido)phenyl sulfamate
(S4) seems to be a very potent one, because of the high CAIX
and CAXII affinity with weak inhibitory capacity towards CAI,
which is highly abundant in red blood cells [14].
S4 is highly effective as an antiproliferative agent through
disruption of pH homeostasis and thereby intracellular processes
in 6 different breast cancer cell lines and in colorectal cancer cell
lines [14,15]. The aim of this study was to examine the effect of
treatment with S4 on the tumor microenvironment in terms of the
anti-proliferative capacity of S4, pro-apoptotic and pro-necrotic
efficacy, and S4-induced changes in hypoxia, metabolism and
CAIX ectodomain shedding. A laryngeal carcinoma tumor model
was chosen based on the association of CAIX expression with a
poor prognosis in head and neck cancer [2].
Materials and Methods
Ethics statement
The experiment was approved by the Animal Experiments
Committee of the Radboud university medical center (Permit
Number RU-DEC 2012-010).
Xenograft tumor model and treatment
In this experiment, the tumor model SCCNij202 was used,
which is derived from a human moderately differentiated
T4N0M0 transglottic laryngeal squamous cell carcinoma.
A power analysis was performed to determine the number of
animals needed to reach statistical significance using the formula
n= 1+2C(s/d)2, where s is the standard deviation, d is the
difference to be detected and C is a constant dependent on the
value of a and b. Using an a of 0.05 and a 1-b of 0.8 results in a C-
value of 7.85. To be able to detect an absolute difference of 7.5%
between groups with an assumed standard deviation of 4.5%, then
n=1+15.7(0.045/0.075)2 = 6.65= 7 mice per group.
Viable 1 mm3 SCCNij202 tumor pieces were implanted
subcutaneously on the hind leg of 6–10 week-old athymic
BALB/c nu/nu female mice. Implantation of tumor pieces was
performed under isoflurane anesthesia. Animals were kept in a
specific pathogen-free unit according to institutional guidelines.
The mice were housed in sterile cages (maximum 11 mice per
cage) with bedding and water, and food provided ad libitum. No
adverse events occurred and weight of the animals was stable
during the experiment. S4 was developed by the research group of
C. Supuran (University of Florence, Italy) [15].
The experiment started when tumors reached a mean diameter
of 6–8 mm. The experimental set-up existed of one control group
and 4 treatment groups, 7 mice per group. Mice were randomly
assigned to the control or treatment groups. Animals were injected
with 0.25 ml vehicle i.p. (37.5% poly ethylene glycol (PEG) 400/
12.5% ethanol/50% 0.9% NaCl) a day for 5 consecutive days
(control group), or with 125 mg per kg body weight S4 dissolved in
37.5% PEG400/12.5% ethanol/50% 0.9% NaCl a day for 1, 3 or
5 consecutive days. Tumors were harvested 8 hours after the last
i.p. injection. Two treatment groups received one S4 i.p. injection.
Tumors of these groups were harvested 8 hours and 24 hours after
the last i.p. injection.
To determine the effects of S4 on proliferation and hypoxia,
animals were injected with 80 mg/kg of the hypoxia marker
pimonidazole (Natural Pharmaceuticals International Inc., Re-
search Triangle Park, NC, USA) one hour before euthanization
and with 50 mg/kg of the proliferation marker bromodeoxyuri-
dine (BrdUrd) (Sigma, St Louis, MO, USA) 15 minutes before
euthanization. Pimonidazole i.p. injection was not successful in
one case. Mice were sacrificed by means of cervical dislocation.
Tumors were snap frozen in liquid nitrogen immediately after
harvest.
Immunohistochemistry
Consecutive sections of 5 mm were stained for CAIX/
pimonidazole/blood vessels, CAIX/BrdUrd/blood vessels/cell
nuclei, and CAIX/caspase-3/blood vessels.
Consecutive steps of the staining procedure were performed as
described previously [16–18]. The antibody against pimonidazole
was a gift of J.A. Raleigh (University of North Carolina). The
antibodies against CAIX, BrdUrd and caspase-3 were purchased
from Novus Biologicals (Littleton, Colorado, USA), Genetex
(Irvine, California, USA) and R&D Systems (Minneapolis,
Minnesota, USA) respectively. 9F1, a rat monoclonal antibody
against mouse endothelium, was a gift of the Department of
Pathology, Radboud university medical center. Primary antibodies
were detected by appropriate Cy3-conjugated (Jackson Immuno
Research Laboratories Inc., West Grove, PA, USA), Alexa488-
conjugated or Alexa647-conjugated (Molecular Probes, Leiden,
The Netherlands) secondary antibodies. Cell nuclei were stained
with Hoechst 33342 (Sigma, Zwijndrecht, the Netherlands).
Image acquisition and analysis
Researchers (T.M. and J.L.) were blinded for the treatment
arms during the analysis of the stained sections. Slides were
scanned using a high-resolution 12-bit CCD camera (Coolsnap
HQ, Roper Scientific Inc., Trenton, NJ, USA) on a fluorescence
microscope (Axioskop, Zeiss, Go¨ttingen, Germany). For each
staining, the exposure time was manually set before scanning.
Thereafter, each section was automatically and completely
scanned at 1006 magnification (on average 144 fields) to yield
grey scale images of the different fluorescent signals. To convert
the grey scale images into binary images, thresholds for the
fluorescent signals were interactively set at intensities where the
steepest gradient occurred between background and foreground
intensity levels [19,20]. The tumor area was marked on the grey
scale images, which excluded non-tumor tissue, necrosis, kerati-
nization and staining artifacts. To allow optimal discrimination
between tumor and non-tumor tissue, a consecutive section was
stained by haematoxylin and eosin (H&E). Using ImageJ software
(NIH, Bethesda, MD, USA), fractions of pimonidazole, CAIX and
caspase-3 were calculated by dividing the tumor area positive for
the marker by the total tumor area [19,20]. The BrdUrd labeling
index (LI) was calculated by dividing the nuclear area positive for
BrdUrd by the total nuclear area of the tumor [20]. To determine
the amount of hypoxia, proliferation and apoptosis within CAIX
positive areas, i.e. the tumor regions in which S4 should be
theoretically effective, a binary closing operation on the CAIX and
pimonidazole signal was performed enabling the assessment of the
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colocalization of the membrane-bound CAIX with the cytoplas-
mic stainings (caspase-3, pimonidazole) or nuclear staining
(BrdUrd). To measure the necrotic fraction, the necrotic area
was marked on the grey scale images. Necrotic fraction was
calculated by dividing the necrotic area by the total tumor area
(including the necrotic area).
Quantitative polymerase chain reactions (qPCR)
Total RNA from fresh frozen tumors (5 sections of 20 mm) was
isolated with the Norgen total RNA purification kit (Norgen Biotek
Corp., Thorold, Canada) and reversed transcribed using the
iScript cDNA synthesis kit (Bio-Rad Laboratories Inc., Richmond,
California, USA) with 1 mg RNA as input. mRNA levels of the
metabolic markers glucose transporter 1 (GLUT1), CAIX, MCT1,
MCT4, NHE1 and V-ATPase ATP6V1C1 were assessed using
qPCR. The C/EBP homologous protein (CHOP), of which the
mRNA level increases with decreasing pH, induces growth arrest
and apoptosis after endoplasmatic reticulum stress or DNA
damage. mRNA level of matrix metallopeptidase 9 (MMP9),
which is involved in breakdown of the extracellular matrix,
declines with decreasing pH [21]. qPCR was performed with
specific primers for CHOP (FW: 59-GGAGCATCAGTCCCC-
CACTT-39, RV: 59-TGTGGGATTGAGGGTCACATC-39),
GLUT1 (FW: 59-GAGCATCATCTTCATCCC-39, RV: 59-
TCTTTAGCACACTCTTGG-39), CAIX (FW: 59-
GAGGCCTGGCCGTGTTG-39), RV: 59-CTGAGCCTTCCT-
CAGCGATT-39), MCT1 (FW: 59-TCTGTGTCTATGCGG-
GATTCTT-39, RV: 59-TTGAGCCGACCTAAAAGTGGT-39),
MCT4 (FW: 59-GTTGGGTTTGGCACTCAACT-39, RV: 59-
GAAGACAGGGCTACCTGC-39), NHE1 (FW: 59-ACCACGA-
GAACGCTCGATTG-39, RV: 59-ACGTGTGTGTAGTC-
GATGCC-39), and the V-ATPase ATP6V1C1 (FW: 59-
GAGTTCTGGCTTATATCTGCTCC-39, RV: 59-
GTGCCAACCTTTAAGTCAGGAAT-39) on a CFX96 real-
time PCR detection system (Bio-Rad Laboratories Inc, Richmond,
California, USA) using SYBR Green. MMP9 qPCR was
performed in Taqman Universal Master Mix with the FW primer
59-ACGCACGACGTCTTCCAGTAC-39 and the RV primer 59-
TAGGTCACGTAGCCCACTTGGT-39, and with the Taqman
probe 59-TCCGGGAACTCACGCGCCAG-39 for signal detec-
tion. Levels are expressed as ratios of hypoxanthine-guanine
phosphoribosyl transferase (HPRT). CAIX qPCR analysis was not
successful in one case.
ELISA CAIX ectodomain shedding
Blood was collected through cardiac puncture immediately after
euthanization. Blood was centrifuged at 3000 rpm for 10 minutes
using the Eppendorf Centrifuge 5804 R and the resulting serum
was stored at 280uC until further processing.
ELISA, which specifically recognizes the human CAIX
ectodomain, was performed as described previously [22,23]. The
capture antibody V/10 (10 mg ml21) was immobilized on the
surface of microplate wells overnight at 4uC. After blocking and
washing, the serum samples diluted 1:2 in PBS were added to the
coated wells for an overnight binding at 4uC. The attached antigen
was then allowed to react with biotinylated MAb M75 diluted
1:5000 (200 ng ml21) in PBS. The amount of bound detector
antibody was determined after 1 hour incubation with the
peroxidase-conjugated streptavidin (Pierce) using a peroxidase
substrate orthophenylene diamine (Sigma).
Statistics
Statistical analyses were performed using Prism 4.0c (GraphPad
Software, Inc., LA Jolla, CA, USA). Changes in fractions, BrdUrd
LI and HPRT ratios were tested for significance using the Kruskal-
Wallis test with Dunn’s post test. Two-sided p-values ,0.05 were
considered statistically significant.
Results
CAIX expression in the SCCNij202 laryngeal carcinoma
xenograft model
The SCCNij202 laryngeal xenograft model was selected on the
basis of its high CAIX expression, thereby expecting a large
therapeutic efficacy of S4. CAIX was often expressed in hypoxic
regions as assessed by pimonidazole staining (Figure 1A). Howev-
er, CAIX expression was also observed in non-pimonidazole areas,
which could indicate intermediate hypoxia as CAIX is upregulated
below a pO2 of 20 mmHg and pimonidazole below a pO2 of
10 mmHg (Figure 1B) [24]. Furthermore, other tumor microen-
vironmental conditions like acidification, tumor suppressors and
oncogenic signaling pathways are able to increase CAIX
expression [25]. Yet, most of CAIX was expressed in pimonida-
zole positive regions in both the control and the treatment groups
(Figure 1C). Proliferative and apoptotic tumor cells were predom-
inantly found in CAIX negative regions (Figure 1D–E).
Effect of CAIX inhibition on the tumor microenvironment
in a laryngeal tumor model
CAIX inhibition using S4 did significantly decrease the amount
of CAIX ectodomain shedding in the serum, especially eight hours
after the first S4 injection (p,0.01) (Figure 2). Median value of the
CAIX ectodomain in the serum declined from 242 pg/ml (control
group) to 13 pg/ml 8 hours after one S4 injection. After 3 S4
injections, median CAIX ectodomain shedding increased to
139 pg/ml (p,0.05) (Figure 2).
Median expression of CAIX and pimonidazole in the control
group was 23.5% (range 16–30%) and 28.5% (range 12–39%)
respectively. S4 changed neither CAIX protein expression nor the
hypoxic fraction. Treatment with S4 did not influence the amount
of cell proliferation and apoptosis, neither within the total tumor
area nor within CAIX expressing regions (Figure 3A–B). Also the
necrotic fraction was not affected by treatment with S4
(Figure 3C).
To assess whether CAIX inhibition with S4 influences
intracellular pH, CHOP mRNA and MMP9 mRNA were
measured as CHOP mRNA increases and MMP9 mRNA declines
with decreasing intracellular pH [21]. However, no changes in
CHOP and MMP9 mRNA were observed (Figure 4). To
determine whether tumor cells were able to adapt to CAIX
inhibition, thereby counteracting changes in intracellular pH,
several transporters and enzymes involved in metabolism and pH
regulation were measured. MCT4 mRNA levels changed signif-
icantly, but this significance was lost using the Dunn’s post test
(Figure 5A). Furthermore, no changes in GLUT1, CAIX, MCT1,
NHE1 and ATP6V1C1 mRNA were observed (Figure 5B–F).
Discussion
CAIX has a pivotal role in pH homeostasis and is associated
with a poor prognosis in several solid tumors [2,3]. The sulfamate
CAIX inhibitor S4 has been shown to decrease tumor cell
proliferation in vitro [14,15]. In this study we examined the effect
of S4 on the tumor microenvironment in a laryngeal tumor model.
CAIX ectodomain shedding
Treatment with S4 decreased CAIX ectodomain shedding,
especially 8 hours after the first i.p. injection, indicating that S4
CAIX Inhibition in Laryngeal Carcinoma Xenografts
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reaches the tumor and that S4 affects the CAIX protein. The
ELISA used for the detection of the CAIX ectodomain in serum is
specific for human CAIX as both V/10 and M75 antibodies only
recognize human and cannot recognize the mouse CAIX [23]. For
this reason, it is impossible that the detected CAIX ectodomain in
the serum is derived from the mouse. This unequivocally shows
that S4 reached the tumor and caused changes in CAIX
ectodomain shedding.
The question remains what the biological and clinical meaning
of this decrease in shedding is. Enzyme-regulated proteolytic
cleavage converts membrane-bound proteins into soluble mole-
cules, a process called ectodomain shedding. In this way, shedding
is a regulatory mechanism that influences the expression of
proteins on the cell surface and the biological function of these
molecules, as these soluble molecules can be biologically active
variants. Furthermore, ectodomain shedding can also result in
intramembrane protein fragments that may be translocated to the
nucleus regulating transcription [26]. CAIX is a very stable
protein (half life 38 hours) that undergoes constitutive shedding,
which is maintained by moderate hypoxia (2%). However, it is
Figure 1. Immunofluorescent images showing CAIX expression, pimonidazole, apoptosis and proliferation in SCCNij202. CAIX is
expressed in hypoxic regions as assessed by pimonidazole staining (A), but is also observed in non-pimonidazole areas (B). Yet, most of CAIX is
expressed in pimonidazole positive regions (C). Proliferation (BrdUrd) and apoptosis (caspase-3) in relation to CAIX expression are shown in figure D
and E respectively. Red, CAIX; Green, pimonidazole (A–B), BrdUrd (D) or caspase-3 (E); Yellow, overlap of CAIX (red) and pimonidazole (green); Light
blue, vessels. Magnification 1006. Scale bars represent 100 mm. Closed circles represent CAIX expression in pimonidazole positive regions; open
circles represent CAIX expression in pimonidazole negative regions. Abbrevations: 16S4, 8 h, one i.p. injection S4, harvest after 8 hours; 16S4, 24 h,
one i.p. injection S4, harvest after 24 hours; 36 S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the last injection; 56 S4, one i.p.
injection S4 a day for 5 days, harvest 8 hours after the last injection.
doi:10.1371/journal.pone.0108068.g001
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unknown whether the CAIX ectodomain has a function in
autocrine or paracrine signaling in cancer biology. Also the
potential intracelluar function of intracellular CAIX fragments is
under investigation [26].
CAIX inhibition, the tumor microenvironment and tumor
growth
We could not confirm the in vitro data that S4 is effective as an
antiproliferative agent in this in vivo tumor model, as measured by
BrdUrd LI [14,15]. Furthermore, S4 was not pro-apoptotic or
pro-necrotic. These observations are fully in line with the data
obtained in a HeLa spheroid model, where S4 treatment resulted
in a transient decrease in CAIX ectodomain shedding (Pastor-
ekova et al., personal communication). Furthermore, no cytotox-
icity as measured by proliferation and cell death was observed, and
the effects on spheroid growth were only transient.
Gieling et al. demonstrated that S4 does not affect primary
tumor growth in a breast carcinoma in vivo model [15]. However,
S4 inhibited breast and thyroid cancer cell migration in vitro and
reduced the number of metastatic tumor colonies in the lung in an
orthotopic xenograft tumor model of the human breast cancer line
MDA-MB-231 [15]. This implies that S4 could reduce the
Figure 2. CAIX ectodomain shedding after treatment with S4.
S4 decreases CAIX ectodomain shedding in the serum, especially
8 hours after the first injection. Abbreviations: CAIX, carbonic anhydrase
IX; 16 S4, 8 h, one i.p. injection S4, harvest after 8 hours; 16 S4, 24 h,
one i.p. injection S4, harvest after 24 hours; 36S4, one i.p. injection S4 a
day for 3 days, harvest 8 hours after the last injection; 56 S4, one i.p.
injection S4 a day for 5 days, harvest 8 hours after the last injection.
doi:10.1371/journal.pone.0108068.g002
Figure 3. No cytotoxic effects of CAIX inhibition in SCCNij202. S4 does not affect proliferation within CAIX positive areas (A), apoptosis within
CAIX positive areas (B) or the amount of necrosis (C). Abbreviations: BrdUrd, bromodeoxyuridine; CAIX, carbonic anhydrase IX; LI, labeling index; NS,
not significant, 16S4, 8 h, one i.p. injection S4, harvest after 8 hours; 16S4, 24 h, one i.p. injection S4, harvest after 24 hours; 36S4, one i.p. injection
S4 a day for 3 days, harvest 8 hours after the last injection; 56 S4, one i.p. injection S4 a day for 5 days, harvest 8 hours after the last injection.
doi:10.1371/journal.pone.0108068.g003
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metastatic burden in the palliative situation and might be able to
inhibit metastasis formation when combined with other systemic
therapies.
Several preclinical studies have investigated the therapeutic
efficacy of other CAIX inhibitors alone and combined with
chemo- or radiotherapy [27–33]. Treatment with the general CA
inhibitor albu-acetazolamide for 3 weeks induced only a partial
inhibition of tumor growth in a renal carcinoma xenograft tumor
model. Sunitinib, which is used as a first-line treatment for
advanced kidney cancer, showed a much stronger delay of tumor
growth relative to albu-acetazolamide. Combination therapy was
only slightly better compared to treatment with sunitinib alone
[27]. Results with albu-acetazolamide were also disappointing in
LS174T colorectal cancer xenograft tumors. Treatment with albu-
acetazolamide for 2 weeks in this tumor model even led to a slight
increase in tumor growth, which however was not statistically
significant compared to the control group. Treatment with 5-
fluorouracil, which is used in the adjuvant setting for colon
carcinoma, yielded a modest tumor growth delay, but the addition
of albu-acetazolamide to 5-FU did not offer a therapeutic synergy
[27]. So, thus far CAIX inhibitors have not demonstrated more
potent anti-tumor activity than current standard first-line treat-
ments.
In contrast to these negative results on primary tumor growth,
other preclinical studies examining CAIX inhibition demonstrated
more promising results [28,29]. Dubois et al. studied the
therapeutic efficacy of 11c, an indanesulfonamide with high
affinity for CAIX, and DH348 in a HT-29 colorectal tumor model
[28,29]. The dual targeting compound DH348 is composed of a 5-
nitroimidazole, which mimics oxygen and thereby sensitizes
tumors to irradiation, and a CAIX-inhibiting sulfamide. Growth
of CAIX-expressing HT-29 tumors was significantly inhibited in
mice treated with 11c or DH348 for 5 days versus mice receiving
vehicle only, which was further increased upon combination with
single dose irradiation. They suggested that the antitumor effect of
CAIX inhibition may be linked to intracelluar acidosis resulting in
apoptosis and decreased proliferation [29]. The CAIX and CAXII
inhibitors ureido-sulfonamide and glycosyl coumarin have been
shown to inhibit primary tumor growth and to limit the
colonization of metastatic tumor cells in the lung in a 4T1 breast
cancer in vivo model [30–32]. However, the efficacy of CAIX
inhibition was not compared with the therapeutic effect of
standard first-line treatments in these preclinical studies.
CAIX is expressed in about 95% of clear cell kidney carcinoma.
In a clinical phase II trial, 36 patients with progressive metastatic
renal cell carcinoma were treated with the CAIX-binding
monoclonal antibody WX-G250 (Rencarex) weekly for 12 weeks.
Patients with stable disease or response after 12 weeks of treatment
continued WX-G250 treatment for additional 8 weeks. Ten
patients had stable disease after the first cycle and received
extended WX-G250 therapy. Eight of 10 patients still showed
stable disease at week 24. One complete response (week 38) and
one significant response (week 44) were observed during follow-up.
Five patients had stable disease for more than 6 months. The
median overall survival was 15 months [34]. The combination of
WX-G250 and interferon-alpha-2a in metastatic renal cell
carcinoma patients with objective disease progression led to
clinically meaningful disease stabilization in 42% of patients,
resulting in a significant longer 2-year survival in responders (79%)
compared to patients with disease progression (30%) [35]. Thus, a
subgroup of patients with kidney carcinoma seems to benefit from
this treatment for metastastic disease control.
CAIX inhibition and pH homeostasis
Several in vitro studies have shown the involvement of CAIX in
the regulation of cellular pH [5,28,29]. Unfortunately, we were
not able to demonstrate a decrease in intracellular pH upon
treatment with S4, measured by the level of CHOP and MMP9
mRNA as indirect references for intracellular pH [21]. However,
CHOP is also strongly induced during hypoxia exposure due to
UPR activation, which may confound our findings [36].
Tumors may have compensated for the inhibition of CAIX
activity resulting in the lack of effect on proliferation, apoptosis
and necrosis. For example, pH regulators might have been not
saturated in the untreated situation and thus could have sufficient
auxiliary capacity to handle the increase in acids upon treatment
with S4. Furthermore, pH regulators can be upregulated through
enhanced transcription or activation of proteins. Chiche et al.
showed that silencing of CAIX is accompanied by upregulation of
CAXII mRNA and protein, resulting in an unchanged extracel-
lular acidification. Furthermore, CAIX was able to compensate for
the lack of NHE1, another important pH regulator [7]. In our
study, CAIX, MCT1, MCT4, NHE1 and V-ATPase ATP6V1C1
Figure 4. Intracellular pH and CAIX inhibition in SCCNij202. S4 does not change CHOP mRNA (A) and MMP9 mRNA (B). Abbreviations: CHOP,
C/EBP homologous protein; MMP9, matrix metallopeptidase 9; NS, not significant; 16S4, 8 h, one i.p. injection S4, harvest after 8 hours; 16S4, 24 h,
one i.p. injection S4, harvest after 24 hours; 36 S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the last injection; 56 S4, one i.p.
injection S4 a day for 5 days, harvest 8 hours after the last injection.
doi:10.1371/journal.pone.0108068.g004
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mRNA levels did not change during treatment with S4. Yet,
cellular pH homeostasis is a very complex process involving a lot of
transporters and enzymes and their isoforms, including mono-
carboxylate transporters, V-ATPases, sodium-hydrogen exchang-
ers, carbonic anhydrases, chloride/bicarbonate exchangers and
natrium/bicarbonate co-transporters amongst others [3,37].
Compensation might have occurred through one or more isoforms
of these regulators at the mRNA or protein level. Another
compensatory mechanism could have been a decreased glucose
metabolism and thereby a reduced production of acids. GLUT1
mRNA levels did not change in our experiment. However,
changes in metabolic activity may have occurred at the protein
level, for example through increased degradation or decreased
activity of glycolytic transporters and enzymes.
Figure 5. Metabolism and CAIX inhibition in SCCNij202. S4 does not influence the expression of several metabolic transporters and enzymes
on the mRNA level. Abbreviations: ATP6V1C1, plasma membrane proton pump vacuolar ATPase (V-ATPase); CAIX, carbonic anhydrase IX; GLUT1,
glucose transporter 1; MCT, monocarboxylate transporter; NHE1, sodium-hydrogen exchanger 1; NS, not significant; 16S4, 8 h, one i.p. injection S4,
harvest after 8 hours; 16S4, 24 h, one i.p. injection S4, harvest after 24 hours; 36S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the
last injection; 56 S4, one i.p. injection S4 a day for 5 days, harvest 8 hours after the last injection.
doi:10.1371/journal.pone.0108068.g005
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Conclusions
In this exploratory study, the effect of the sulfamate CAIX
inhibitor S4 on the tumor microenvironment was characterized in
a laryngeal tumor model. CAIX ectodomain shedding into the
blood stream was decreased by S4. As the meaning of this
observation is not clear, further studies are required to elucidate
whether the CAIX ectodomain has a paracrine or autocrine
signalling function in cancer biology. S4 did not influence the
tumor microenvironment in a laryngeal tumor model in terms of
the amount of proliferation, apoptosis, necrosis and hypoxia.
Another preclinical in vivo mice study could not demonstrate an
effect of S4 on primary tumor growth [15]. Therefore, S4 does not
seem to be successful as single agent to influence tumor cell kill
(apoptosis, necrosis) and proliferation, and to target primary tumor
growth.
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